Trending Now
Palisade Bio Inc (NASDAQ: PALI) Commences Dosing Of Patients In Phase...
Palisade Bio Inc (NASDAQ: PALI) has announced the dosing of the first patient in the third phase LB1148 assessment to accelerate bowel function restoration...
DIH Holding US, Inc. (DHAI): Pioneering Rehabilitation with Cutting-Edge Technology
Let’s talk about something truly inspiring: the future of rehabilitation. On December 23, 2024, DIH Holding US, Inc. (NASDAQ: DHAI) announced...
Predictive Oncology Inc. (Nasdaq: POAI): A Transformative Acquisition by Renovaro Inc.
The biotechnological domain is currently abuzz with developments surrounding the acquisition of Predictive Oncology Inc. (Nasdaq: POAI) by Renovaro Inc. (Nasdaq: RENB)....
Popular News
Geron Corporation (NASDAQ:GERN) Releases Q1 Results Says It Has Enough Cash...
Geron Corporation (NASDAQ:GERN) has announced its Q1 2020 financial results for the quarter ended March 31, 2020.
Geron has enough cash to last it the...
MAKE IT MODERN
LATEST REVIEWS
Clubhouse Media (CMGR) Sets Sights on Surging NFT Market (PLBY, FNKO,...
One of the most interesting trends to recently emerge across markets is the enthusiastic surge in interest in NFTs, or non-fungible tokens.
MAKE IT MODERN
PERFORMANCE TRAINING
Why the Pullback in Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) is Likely a Gift
Without doubt, one of the
strongest stories in the biotech space over recent months has been Arrowhead
Pharmaceuticals Inc (NASDAQ:ARWR). Shares have powered well...
Citius Pharmaceuticals Inc. (NASDAQ: CTXR) Finalizes Patient Enrolment In Pivotal Phase 3 I/ONTAK Study
Citius Pharmaceuticals Inc. (NASDAQ: CTXR) has announced that it has finalized patient enrolment in the Pivotal Phase 3 study of its engineered IL-2-diphtheria toxin...
EV Battery Boom Stocks Could Define 2022 (QS, CEI, RMO, XPEV, TSLA, ALB, PLUG,...
The energy storage boom stands to be one of the defining explosive trends of the next decade. And it is clearly still...
Affimed Inc. (NASDAQ:AFMD) Publishes Phase 1b Study Results Evaluating AFM13 Combination With KEYTRUDA In...
Affimed Inc. (NASDAQ:AFMD) has announced the publication of the Phase 1b combination study of AFM13, its CD30/CD16A innate cell engager (ICE®) with...
Matinas BioPharma Holdings Inc (NYSE: MTNB) Executes a Partnership Agreement With BioNTech SE (NASDAQ:...
Matinas BioPharma Holdings Inc (NYSE: MTNB) recently announced the execution of a partnership agreement with BioNTech SE (NASDAQ: BNTX). The partnership agreement is to...